Market Outlook

By 2035, the U.S. Diabetes Management Devices Market is expected to reach approximately USD 59.20 billion, expanding at a CAGR of 10.69% during the forecast period 2026–2035. The market was valued at approximately USD 21.45 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

The U.S. diabetes management devices industry has moved from a conventional glucose-testing and insulin-delivery market into one of the most strategically important connected-medical-device ecosystems in American healthcare. The addressable patient population is substantial: approximately 40.1 million people in the United States were estimated to have diagnosed or undiagnosed diabetes in 2023, while approximately 115.2 million adults had prediabetes. The diagnosed population alone exceeds 29 million people, creating a large recurring requirement for glucose monitoring, insulin delivery, sensors, infusion supplies, needles, lancets, software-linked devices, and automated glycemic-management technologies.

The commercial value pool is shifting decisively toward continuous glucose monitoring, wearable insulin delivery, automated insulin delivery systems, interoperable devices, smartphone-controlled therapy, longer-wear sensors, and data-supported diabetes management. Traditional blood glucose meters and testing strips remain clinically relevant, particularly as backup technologies and in lower-cost settings, but they no longer define the innovation trajectory of the market. Device manufacturers are increasingly competing on sensor duration, accuracy, form factor, interoperability, pharmacy access, reimbursement simplicity, patient onboarding, software usability, algorithm performance, and the ability to reduce the daily cognitive burden of diabetes management.

The historical market increased from an estimated USD 12.85 billion in 2021 to USD 14.55 billion in 2022, USD 16.85 billion in 2023, and USD 19.20 billion in 2024, reaching USD 21.45 billion in 2025. Expansion during this period was supported by accelerating CGM adoption, broader Medicare access, stronger commercial payer coverage, rapid penetration of tubeless insulin pumps, growing use of automated insulin delivery, and migration of selected diabetes technologies from the durable-medical-equipment channel toward pharmacy-centered distribution.

The forecast trajectory remains aggressive because diabetes technology is expanding beyond the traditional intensive-insulin population. FDA actions supporting over-the-counter CGM and automated insulin dosing for adults with type 2 diabetes materially widen the potential user pool. Manufacturers are therefore moving from a relatively narrow type 1 diabetes technology market toward a much larger continuum that includes insulin-treated type 2 diabetes, non-insulin-treated type 2 diabetes, people at risk of hypoglycemia, and selected consumers seeking structured glucose information.

Market sizing in this report represents a syndicated analyst estimate based on manufacturer-reported device revenue, U.S. sales exposure, recurring consumable utilization, installed patient bases, replacement cycles, reimbursement access, product pricing, and channel economics. The scope includes glucose monitoring devices, diabetes-specific insulin delivery hardware and consumables, automated insulin delivery systems, smart insulin administration technologies, and device-linked diabetes management platforms. Prescription drugs including insulin, GLP-1 therapies and oral antidiabetic medicines are excluded.

 

Introduction

According to the U.S. Diabetes Management Devices Market Report, diabetes care is undergoing a structural shift from intermittent measurement and manually calculated therapy toward persistent sensing, algorithm-assisted decision-making, automated insulin delivery, and longitudinal data management. This transition is altering both patient behavior and the commercial economics of diabetes technology.

Diabetes is particularly attractive to device manufacturers because management is continuous rather than episodic. A person using CGM may require a new wearable sensor every 10 to 15 days, while insulin-pump users consume infusion sets, cartridges, reservoirs, or disposable pods repeatedly throughout the year. Consequently, a successful device placement generates recurring consumable revenue and long-duration patient relationships. Switching costs can also become meaningful once patients, clinicians, caregivers, smartphone applications, cloud platforms, and supply channels are integrated around a particular ecosystem.

The economic burden of the disease reinforces the strategic importance of better diabetes management. The annual U.S. economic cost of diagnosed diabetes reached approximately USD 412.9 billion in 2022, including more than USD 300 billion in direct medical expenditure. Diabetes is associated with costly cardiovascular, renal, ophthalmic, neurologic, and lower-extremity complications, creating strong payer and provider incentives to improve glucose control and identify deterioration earlier.

The U.S. market also benefits from a mature reimbursement environment. Medicare covers qualifying CGM systems and related supplies for insulin-treated beneficiaries and certain patients with documented problematic hypoglycemia. Commercial insurers, Medicare Advantage organizations, Medicaid programs, employer plans, pharmacy benefit structures, and DME channels create multiple pathways to device access, although coverage requirements, prior authorization, formulary positioning, patient cost sharing, and supplier contracting continue to influence product choice.

From 2026 through 2035, the central strategic shift will be from standalone diabetes devices to interconnected therapy ecosystems. Manufacturers able to combine sensing, insulin delivery, algorithms, patient-facing applications, clinician dashboards, remote monitoring, decision support, and evidence generation will have a stronger competitive position than companies dependent on isolated hardware categories.

 

Key Market Drivers: What’s Fueling the U.S. Diabetes Management Devices Market?

The largest underlying driver is the scale and persistence of diabetes in the United States. Approximately 40.1 million people were estimated to have diabetes in 2023, while 29.1 million had diagnosed disease. Type 2 diabetes accounts for approximately 90%–95% of diagnosed adult cases, giving manufacturers an addressable population far larger than the historically technology-intensive type 1 diabetes segment. An additional 1.5 million adults were newly diagnosed in 2023, continuously replenishing the population requiring glucose monitoring and disease-management support.

The second driver is the rapid normalization of continuous glucose monitoring. CGM has evolved from a specialized technology primarily used by intensively managed type 1 diabetes patients into a mainstream diabetes-management platform. Improved sensor accuracy, smaller wearable formats, longer wear periods, smartphone integration, simplified insertion, predictive alerts, lower patient friction, and broader reimbursement are accelerating substitution away from conventional fingerstick testing in suitable populations.

The third driver is expansion of reimbursement eligibility. Medicare coverage criteria now allow qualifying beneficiaries to receive CGM when they are insulin-treated or have a documented history of problematic hypoglycemia. The removal of older intensive-insulin requirements significantly enlarges the addressable Medicare population. For manufacturers, reimbursement expansion has implications beyond unit demand: it supports clinician familiarity, increases distributor participation, strengthens patient awareness, and encourages commercial insurers to reassess their own coverage policies.

The fourth driver is automated insulin delivery. The combination of an insulin pump, interoperable CGM and algorithmic controller can automatically adjust insulin based on glucose readings. AID reduces the number of manual therapeutic decisions patients must make each day and changes competition from individual products toward integrated ecosystems. FDA expansion of automated insulin dosing technology into adults with type 2 diabetes represents an important commercial inflection point because the pump market has historically been concentrated in type 1 diabetes.

The fifth driver is growing preference for wearable and lower-burden insulin delivery. Tubeless pumps, compact durable pumps, wearable patch systems, mobile control, smart insulin pens and connected dose-tracking technologies are reducing the inconvenience associated with traditional insulin administration. Insulet’s U.S. Omnipod revenue expanded strongly in 2025, while Tandem continued to ship substantial numbers of insulin pumps in the United States. These commercial results demonstrate that insulin-delivery innovation continues to attract users despite an increasingly competitive treatment environment.

Another important driver is movement toward pharmacy-oriented access. Historically, many advanced diabetes devices were distributed primarily through DME suppliers, creating administrative complexity and longer onboarding cycles. Pharmacy access can reduce fulfillment friction, simplify benefit verification and bring diabetes devices into a purchasing environment already familiar to patients using insulin and other medications. Manufacturers are consequently experimenting with pharmacy-first or hybrid commercial models.

A further driver is the importance of complication prevention. Diabetes contributes to kidney disease, cardiovascular events, vision impairment, neuropathy and lower-extremity complications. Devices that improve time in range, detect hypoglycemia earlier, reduce severe glucose excursions or strengthen therapy adherence can therefore generate economic value beyond their purchase price. Payers increasingly examine downstream medical utilization when assessing premium diabetes technologies.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Continuous glucose monitoring represents the most visible innovation cycle in U.S. diabetes technology. Competition is moving toward smaller sensors, extended wear, faster warm-up, fewer calibrations, improved accuracy, more reliable Bluetooth connectivity, integrated smartphone applications and lower manufacturing cost per sensor-day. Fifteen-day wear and related longer-duration strategies are particularly important because reduced replacement frequency can improve convenience while lowering logistics burden.

Over-the-counter CGM is creating another category boundary. The FDA cleared the first OTC CGM in 2024, eliminating the prescription requirement for specified adult populations. Additional OTC products subsequently broadened competition. This creates a potential market among adults with non-insulin-treated type 2 diabetes and other eligible users who historically had limited access to continuous glucose information. It also introduces consumer-device economics, including direct payment, digital acquisition, subscription behavior and retail merchandising, into a market traditionally governed by medical reimbursement.

Automated insulin delivery is simultaneously becoming more sophisticated. Current-generation systems use CGM data to alter basal insulin delivery and, depending on the system, provide automated correction functionality. Innovation is increasingly centered on algorithm personalization, reduced meal-announcement burden, improved exercise handling, tighter glucose targets, more time spent in automated mode, easier onboarding, and interoperability across multiple sensors.

The FDA’s 2024 expansion of Insulet’s SmartAdjust technology into adults with type 2 diabetes was strategically important because it demonstrated that automated insulin dosing is no longer necessarily confined to type 1 diabetes. The addressable opportunity is substantial because even modest penetration among insulin-treated type 2 patients could materially expand pump and recurring consumable revenue.

Connected insulin administration is another emerging area. Smart pens, connected pen caps and dose-tracking systems can capture injection timing and dosage, integrate CGM information, identify missed doses and support insulin calculations without requiring a pump. This model is relevant for patients who prefer injections, cannot access pump therapy, or do not require the complexity of an AID system.

Device interoperability is becoming a competitive requirement rather than an optional feature. Patients increasingly expect their CGM, insulin pump, smartphone, smartwatch, dose-calculation software and clinician-facing platform to work together. Manufacturers that remain within closed proprietary ecosystems may retain control over economics, but open or multi-partner interoperability can expand patient choice and commercial reach.

Software is also becoming a larger component of device differentiation. Diabetes platforms increasingly summarize time in range, glucose variability, hypoglycemia exposure, insulin delivery patterns and treatment adherence. For endocrinologists managing hundreds or thousands of connected patients, the commercial value of a device increasingly depends on whether its data can be reviewed efficiently without adding excessive clinician workload.

Manufacturing innovation is equally important. CGM and wearable-pump companies require high-volume automated production because recurring sensors and disposable pods generate substantial unit demand. Scale economics affect gross margin, pricing flexibility, supply continuity and the ability to address cost-sensitive type 2 and OTC populations. The competitive race is therefore not only clinical; it is also a manufacturing and supply-chain race.

 

Segmentation Insights

The U.S. Diabetes Management Devices Market is segmented on the basis of product type, diabetes type, end user, distribution channel, and region.

 

By Product Type

Continuous Glucose Monitoring Systems

Continuous glucose monitoring systems represent the largest and fastest-expanding major product category, accounting for an estimated USD 8.58 billion in U.S. market value in 2025. The segment includes wearable sensors, transmitters where required, readers, receivers and related accessories.

CGM adoption is being driven by improved patient experience and a superior information model compared with intermittent testing. Instead of producing a single glucose reading, CGM provides trends and directional information that can support more informed insulin, diet and activity decisions. The technology is increasingly integrated into insulin pumps, digital diabetes platforms and clinician workflows.

The segment is led primarily by Abbott and Dexcom, with Medtronic and other companies maintaining positions in selected patient populations and integrated therapy platforms. Dexcom generated USD 4.662 billion in worldwide revenue during 2025 and reported 15% U.S. revenue growth, while Abbott continued to report double-digit growth for its CGM portfolio. These commercial results illustrate the scale at which wearable glucose sensing has developed.

Blood Glucose Monitoring Systems

Traditional blood glucose monitoring represented an estimated USD 3.86 billion in 2025 and includes glucose meters, test strips, lancets and associated consumables. The segment is mature and is losing share to CGM among highly engaged and well-covered patients, but it remains clinically and commercially relevant.

Fingerstick meters remain important for confirmatory measurements, backup testing, newly diagnosed users, non-insulin-treated patients, inpatient and outpatient clinical environments, and populations facing affordability or coverage limitations. Test strips also generate recurring revenue, although pricing pressure is considerably greater than in premium CGM.

The future of this segment will increasingly depend on low-cost manufacturing, retail availability, private-label economics, connectivity and integration with digital management applications rather than major improvements to basic glucose-meter hardware.

Insulin Pumps and Automated Insulin Delivery Systems

Insulin pumps and AID systems represented approximately USD 4.29 billion in 2025. This category includes tubeless wearable pumps, conventional durable pumps, disposable insulin-delivery components, infusion sets, cartridges and algorithm-linked pump platforms.

Tubeless pumps are reshaping procurement and patient preference because they remove external tubing and frequently use recurring disposable pods. Insulet reported approximately USD 1.92 billion in U.S. Omnipod revenue during 2025, increasing more than 27% year over year. Tandem generated approximately USD 706.9 million in 2025 U.S. sales and shipped more than 86,000 pumps domestically.

Growth through 2035 will come from conversion of multiple-daily-injection users, increasing AID utilization within type 1 diabetes, expanded use among insulin-treated type 2 diabetes, pharmacy distribution, easier onboarding and increased interoperability between pumps and competing CGM platforms.

Insulin Pens, Smart Pens, Pen Needles and Injection Devices

Injection-based insulin delivery products represented approximately USD 3.22 billion in 2025. The category includes reusable and disposable delivery devices where device revenue is identifiable, smart insulin pens, connected pen technologies, pen needles, insulin syringes and related administration products. Drug value is excluded from the market estimate.

Despite strong pump growth, multiple daily injections will remain a major treatment approach through the forecast period. Many type 2 diabetes patients who require insulin will not immediately transition to pump therapy because of clinical preference, cost, training requirements or personal choice. Consequently, pen needles and injection-support devices provide a large recurring-volume market.

Connected pens offer a higher-value growth opportunity because they can combine injection therapy with dose capture, reminders, insulin-on-board calculations and CGM information. These platforms occupy an important middle position between basic injections and fully automated pump therapy.

Digital, Connected and Other Diabetes Management Devices

Digital and connected devices represented approximately USD 1.50 billion in 2025. This includes device-linked controllers, dedicated handheld interfaces, connected dose-management products and other eligible diabetes-specific management technologies where device or hardware-linked revenue can be identified.

The strategic importance of this segment is greater than its current revenue share. Software increasingly determines device usability, data-sharing capability, clinician engagement and interoperability. Over time, artificial intelligence and predictive analytics are expected to improve alert prioritization, therapy adjustment and personalized device settings.

 

By Diabetes Type

Type 2 Diabetes

Type 2 diabetes represents the largest market by aggregate value, accounting for approximately USD 14.37 billion in 2025. Approximately 90%–95% of diagnosed adult diabetes cases are type 2, giving this category an exceptionally large patient base.

Historically, technology intensity was significantly lower than in type 1 diabetes because many patients were treated with lifestyle changes, oral medications or non-insulin injectables. This is changing. Broader CGM access, OTC sensing, simplified wearables and regulatory expansion of automated insulin delivery are moving high-value devices deeper into the type 2 population.

Type 2 therefore represents the largest incremental growth opportunity through 2035. Even relatively low additional penetration of CGM among non-intensive insulin users and selected non-insulin-treated patients could create several billion dollars of incremental annual device demand.

Type 1 Diabetes

Type 1 diabetes represented approximately USD 6.22 billion in device spending in 2025, despite its substantially smaller patient population. The United States had approximately 2.1 million people with diagnosed type 1 diabetes in 2023, including about 1.8 million adults and more than 300,000 children and adolescents.

Device intensity is considerably higher because most patients require continuous insulin therapy throughout life. Type 1 users are the core adopters of CGM, insulin pumps and AID technology, making this population strategically critical to Abbott, Dexcom, Insulet, Medtronic, Tandem, Beta Bionics and other diabetes technology companies.

Future value growth will come from higher AID penetration, pump conversion, pediatric adoption, longer sensor wear, interoperability, improved algorithms and recurring supply revenue rather than major expansion of the underlying disease population.

Gestational and Other Diabetes

Gestational diabetes and other specified diabetes categories represented an estimated USD 0.86 billion in 2025. Device demand is concentrated in glucose monitoring, short-duration management and selected insulin-delivery requirements.

This category is smaller but clinically important because pregnancy requires tight glycemic management. CGM manufacturers are increasingly interested in expanding evidence and regulatory positioning in pregnancy because continuous information can potentially improve treatment oversight compared with intermittent readings alone.

 

By End User

Home and Individual Diabetes Management

Home and individual self-management is the dominant end-user segment, representing approximately USD 16.30 billion in 2025. Diabetes devices are fundamentally designed for continuous patient interaction. CGM sensors, meters, insulin pumps, pens and related supplies are used primarily outside hospitals, making ease of use, training and adherence central commercial considerations.

The growing shift toward smartphone-controlled and remotely connected care strengthens the home setting further. Device companies increasingly design technology around self-application, automated data upload, remote troubleshooting and digital education rather than frequent in-person clinical intervention.

Hospitals and Health Systems

Hospitals and integrated health systems represented approximately USD 2.15 billion in 2025. Their direct product consumption is lower than the home market, but their strategic influence is disproportionately large. Health systems diagnose patients, initiate therapy, operate endocrinology programs and frequently shape the device preference that patients continue using after discharge.

Hospital diabetes management also requires bedside glucose testing, inpatient monitoring and safe insulin-delivery workflows. Integration with electronic health records and clinical protocols will become more important as connected diabetes technologies move into inpatient care.

Endocrinology and Diabetes Specialty Centers

Endocrinology practices and diabetes specialty centers represented approximately USD 1.72 billion in attributable device demand in 2025. These centers are important adoption gateways for CGM and AID because clinicians evaluate device suitability, prescribe products, review data and provide training.

Manufacturers compete heavily for specialist preference. Products that reduce onboarding time and simplify data review can gain an advantage because endocrinology practices face significant patient volumes and administrative burden.

Home Healthcare, Long-Term Care and Assisted Living

Home healthcare, long-term care and assisted-living settings represented approximately USD 0.64 billion in 2025. The aging U.S. population makes this an increasingly relevant diabetes-device segment, particularly because diabetes prevalence rises sharply among older adults.

Simplified monitoring, caregiver data access, reduced fingerstick requirements and hypoglycemia alerts may improve diabetes-management workflows in elderly populations. Procurement, however, remains sensitive to reimbursement, staff training and interoperability.

Research, Education and Other Clinical Users

Research institutions, diabetes education programs and other clinical environments represented approximately USD 0.64 billion in 2025. Their revenue contribution is modest, but they play an important role in clinical evidence generation, patient training and the evaluation of new device technologies.

 

By Distribution Channel

Retail and Pharmacy Channel

Retail and pharmacy distribution accounted for approximately USD 7.08 billion in 2025. This channel is gaining strategic importance as CGM and pump manufacturers seek to reduce DME complexity and place diabetes technology alongside prescription medications.

Pharmacy distribution can improve speed to therapy, reduce administrative friction and create more transparent patient benefit structures. OTC CGM adds another dimension by enabling eligible products to move through direct retail and consumer channels without conventional prescription workflows.

Durable Medical Equipment and Medical Supply Providers

DME and specialized medical supply channels represented approximately USD 6.01 billion in 2025. They remain central to Medicare-covered CGM, traditional pump equipment and recurring diabetes supplies.

DME suppliers perform benefit verification, claims processing, recurring supply fulfillment and patient support. The segment will remain important, although manufacturers are working to balance it against pharmacy access in order to reduce onboarding delays.

Direct-to-Consumer and E-commerce

Direct and digital commerce represented approximately USD 3.86 billion in 2025. This channel includes manufacturer-direct fulfillment and eligible online purchasing models.

Growth will accelerate as diabetes devices become simpler, as OTC sensing expands, and as manufacturers invest more heavily in direct patient acquisition. The economics differ from traditional medtech because companies must manage consumer marketing costs, subscription retention, fulfillment and digital support.

Hospital and Institutional Procurement

Hospital and institutional channels represented approximately USD 2.57 billion in 2025. Procurement decisions emphasize device reliability, standardization, safety, compatibility with clinical workflow and total episode economics.

Large health systems can influence outpatient market share through formulary relationships, clinician preference and discharge pathways even when devices are ultimately purchased elsewhere.

Specialty and Other Channels

Specialty distributors and other diabetes-specific supply channels represented approximately USD 1.93 billion in 2025. These organizations are particularly relevant where payer requirements, complex documentation or high-touch patient training make general retail fulfillment less suitable.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Diabetes Management Devices Market is geographically segmented into the South, West, Northeast and Midwest. Geographic demand is influenced by diabetes prevalence, population size, Medicare enrollment, obesity burden, insurance coverage, endocrinology access, urban-rural distribution, pharmacy infrastructure and adoption of premium diabetes technologies.

The South represented the largest regional market at approximately USD 8.58 billion in 2025, followed by the West at USD 4.93 billion, the Northeast at USD 4.08 billion, and the Midwest at USD 3.86 billion. The West is expected to record the fastest growth through 2035, while the South will retain the largest absolute revenue opportunity.

National surveillance demonstrates why geography matters. Diagnosed diabetes prevalence differs substantially across states and counties, with CDC data showing a U.S. state median around 10% and county-level prevalence ranging considerably wider. The Southeast has a particularly dense concentration of high-prevalence counties. Rural areas in the South also show substantially higher diagnosed diabetes prevalence than large metropolitan populations, creating a clinically attractive but operationally challenging market for remote and simplified diabetes technologies.

South

The South is the largest U.S. diabetes management devices market and is projected to increase from approximately USD 8.58 billion in 2025 to USD 23.80 billion by 2035, representing an estimated CAGR of about 10.74%.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma and the District of Columbia.

The South combines the country’s largest concentration of high-diabetes-burden communities with several of its fastest-growing metropolitan populations. CDC research has consistently shown a geographic concentration of elevated diagnosed diabetes prevalence across the Southeast and Appalachia. Rural Southern counties also demonstrate particularly high diabetes prevalence, strengthening demand for products that reduce dependence on frequent specialist visits.

Texas is one of the largest individual state opportunities because of its population size, major healthcare markets in Houston, Dallas–Fort Worth, Austin and San Antonio, expanding Medicare population and large base of people with type 2 diabetes. Commercial opportunity spans premium CGM and pump technologies in metropolitan markets and more cost-sensitive glucose-monitoring solutions in rural communities.

Florida represents another strategically important state because of its large older population. Medicare reimbursement is therefore particularly influential. CGM companies, DME suppliers and pharmacy networks have significant opportunity in the state as diabetes prevalence intersects with an aging population requiring cardiovascular, renal and metabolic disease management.

Georgia and North Carolina combine substantial diabetes burden with rapidly growing health systems. Atlanta, Charlotte, Raleigh-Durham and surrounding markets support specialist-led adoption of CGM and AID, while rural portions of both states create demand for remote management and simplified device distribution.

Virginia and Maryland have strong integrated delivery networks and sophisticated specialist infrastructure. Northern Virginia, Richmond, Baltimore and the Washington metropolitan region support adoption of connected diabetes platforms, while rural areas require different pricing and access strategies.

Tennessee, Kentucky and West Virginia represent important Appalachian diabetes markets. Higher chronic-disease burden creates substantial clinical need, but device penetration can be constrained by specialist availability, socioeconomic barriers and uneven commercial coverage. Manufacturers that combine reimbursement support, pharmacy access and remote training may perform better than those relying exclusively on endocrinology-centered sales models.

Alabama and Mississippi are especially relevant because of high diabetes and obesity burden. These markets have strong need for monitoring technology but also highlight the affordability challenge facing the industry. Lower-cost CGM, broader Medicaid access and simplified supply models could substantially expand adoption.

Arkansas, Louisiana and Oklahoma combine meaningful diabetes prevalence with sizeable rural populations. Connected CGM and remote support can reduce some geographic barriers, but dependable cellular connectivity, pharmacy access and patient education remain considerations.

South Carolina and Delaware are smaller markets by absolute value but continue to benefit from aging populations and expanding outpatient care. The District of Columbia represents a small but high-density healthcare market with substantial academic and specialist infrastructure.

Given the scale of disease burden and population growth, the South should remain the leading regional revenue pool throughout the forecast period.

West

The West represented approximately USD 4.93 billion in 2025 and is expected to reach around USD 15.50 billion by 2035, producing the fastest regional CAGR at approximately 12.14%.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

The West has a comparatively lower overall diabetes burden than parts of the South but compensates through rapid population growth, high digital-health acceptance, advanced provider infrastructure and strong adoption of wearable technologies.

California is the dominant Western state and one of the largest diabetes technology markets nationally. Its scale alone produces substantial glucose-monitoring demand, while major academic and integrated health systems support rapid evaluation of advanced CGM, AID and connected insulin technologies. California is also strategically important because Dexcom is headquartered in the state and Abbott Diabetes Care has major operations there, creating a significant diabetes-technology innovation ecosystem.

Arizona and Nevada are attractive high-growth markets because of population migration and increasing older-adult populations. Phoenix, Tucson and Las Vegas provide concentrated commercial opportunities for CGM, insulin pumps and pharmacy-distributed technologies.

Washington and Oregon have strong digital-health adoption, integrated delivery systems and technologically sophisticated patient populations. Seattle and Portland frequently provide favorable environments for connected devices and remote diabetes-management models.

Colorado and Utah combine growing populations with relatively sophisticated health systems. Denver, Salt Lake City and surrounding markets support strong adoption of wearable and app-integrated diabetes technology.

New Mexico has substantial diabetes burden and important rural and Native American populations. Access disparities create a strong need for low-friction monitoring technologies, although affordability and geographic access require tailored commercialization.

Idaho, Montana and Wyoming represent smaller but strategically relevant rural markets. Remote diabetes management can provide particular value because specialist access often requires long-distance travel.

Alaska has unique logistical constraints, making reliable supply distribution and remote care highly valuable. Hawaii similarly represents a geographically isolated market where diabetes prevalence among selected populations supports continued demand for monitoring and insulin-delivery technologies.

The West is likely to gain national market share because diabetes-device growth is increasingly linked to wearable technology, direct consumer access, digital connectivity and pharmacy distribution rather than disease prevalence alone.

Northeast

The Northeast accounted for approximately USD 4.08 billion in 2025 and is forecast to reach around USD 10.70 billion by 2035, reflecting a CAGR of approximately 10.12%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, New Hampshire, Rhode Island and Vermont.

The Northeast is a mature but premium-oriented diabetes technology market. It has high specialist density, strong academic medical centers, extensive commercial insurance coverage and sophisticated integrated delivery networks. These characteristics support faster adoption of clinically differentiated technologies despite slower population growth.

New York is the region’s largest market due to population scale and the concentration of major provider systems in New York City, Long Island, Westchester, Buffalo, Rochester and other metropolitan areas. Diabetes technology adoption is supported by endocrinology networks, academic centers and extensive retail pharmacy infrastructure.

Pennsylvania combines large urban markets in Philadelphia and Pittsburgh with substantial rural and post-industrial populations. This produces a mixed market requiring premium technology in academic centers and access-oriented strategies elsewhere.

New Jersey benefits from high population density, significant commercial insurance exposure, large pharmaceutical and medical-technology employment, and proximity to major New York and Philadelphia healthcare ecosystems.

Massachusetts is disproportionately influential because of Boston’s academic, biotechnology and medical-device ecosystem. Although the state is smaller by population, clinicians and research centers can influence evidence generation and national adoption of diabetes technologies.

Connecticut, Rhode Island and New Hampshire are comparatively small but affluent markets with strong health-system access. Maine and Vermont have more dispersed populations and larger rural components, increasing the relevance of remote monitoring and simplified distribution.

The Northeast should remain attractive for premium CGM, AID, connected insulin delivery and emerging algorithm-driven technologies because provider organizations in the region generally place substantial weight on clinical evidence and patient outcomes.

Midwest

The Midwest represented approximately USD 3.86 billion in 2025 and is expected to reach approximately USD 9.20 billion by 2035, expanding at an estimated CAGR of 9.07%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

The Midwest provides a stable market supported by large hospital systems, mature diabetes-care networks, meaningful chronic disease burden and a substantial Medicare population.

Illinois is the region’s largest technology market, with Chicago providing a major concentration of academic medical centers, endocrinologists, pharmacies and commercially insured patients.

Ohio and Michigan have large diabetes populations and extensive regional health systems. Cleveland, Columbus, Cincinnati and Detroit support advanced diabetes technology, while smaller cities and rural communities strengthen demand for cost-effective monitoring solutions.

Minnesota is particularly important strategically because of its global medtech ecosystem and Medtronic’s historic role in insulin-pump technology. Health systems in the state are generally sophisticated users of connected medical technology.

Indiana, Wisconsin and Missouri have meaningful diabetes burden and large hospital networks. Indianapolis, Milwaukee, Madison, St. Louis and Kansas City serve as regional hubs for endocrinology and advanced diabetes care.

Iowa, Kansas and Nebraska have smaller populations but meaningful rural-care requirements. Connected monitoring, mail-order fulfillment and pharmacy-centered supply models can improve access outside large metropolitan areas.

North Dakota and South Dakota represent the smallest absolute markets in the region but demonstrate the value proposition of remote diabetes management because specialist care can be geographically concentrated.

The Midwest is expected to grow more slowly than the West or South, but its recurring consumable demand, broad insurance base and established provider relationships make it a durable commercial market.

 

Key Market Players

The U.S. Diabetes Management Devices Competitive Landscape is concentrated at the top of the CGM and insulin-pump markets but remains fragmented across traditional glucose monitoring, injection devices, software, distribution and emerging diabetes technology.

Competition is increasingly ecosystem-based. Abbott and Dexcom are competing not simply for standalone CGM users but for positions inside insulin-delivery and digital-management ecosystems. Insulet, Tandem, Medtronic and Beta Bionics are competing on automated insulin delivery, usability, algorithms, CGM partnerships and form factor. Traditional diabetes companies remain important in injection devices, blood glucose monitoring and consumables.

Some of the key companies active in the U.S. Diabetes Management Devices Market include:

Abbott Laboratories
DexCom, Inc.
Insulet Corporation
Medtronic plc
Tandem Diabetes Care, Inc.
Beta Bionics, Inc.
Roche Diabetes Care
Ascensia Diabetes Care
LifeScan
Embecta Corp.
Becton, Dickinson and Company
Novo Nordisk
Eli Lilly and Company
Sanofi
Ypsomed Holding AG
Senseonics Holdings, Inc.
Eversense / Ascensia Diabetes Care
AgaMatrix
Trividia Health
Prodigy Diabetes Care
Diamesco
i-SENS
Nipro Corporation
Terumo Corporation
Glooko

Abbott and Dexcom currently hold the strongest positions in U.S. CGM, while Insulet, Medtronic and Tandem represent major insulin-pump competitors. Beta Bionics has strengthened competition in automated insulin delivery through its iLet platform. Embecta, BD and other injection-device manufacturers remain relevant where multiple daily injections continue to dominate.

The competitive structure is also becoming more partnership-dependent. CGM companies increasingly need connectivity with multiple pumps; pump manufacturers require reliable sensor partnerships; pharmaceutical companies are exploring connected injection strategies; and diabetes-device companies require pharmacy, DME, payer and digital-health relationships.

Future market share will be influenced by sensor cost per day, wear duration, accuracy, AID performance, interoperability, pharmacy coverage, Medicare access, formulary placement, patient acquisition economics, manufacturing scale, product reliability and the ability to generate convincing real-world evidence.

 

Recent Developments

Recent developments in the U.S. Diabetes Management Devices Market demonstrate that the industry’s addressable population is expanding beyond its traditional boundaries.

In March 2024, the FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor in the United States. The clearance was significant because eligible adult users could purchase continuous glucose sensing without a prescription. It created a new commercial pathway for people who do not use insulin and for other eligible consumers seeking glucose information.

In June 2024, FDA clearance of Abbott’s Libre Rio further expanded OTC CGM competition. Abbott also moved forward with Lingo, extending sensor technology toward a broader consumer market. These developments signal a transition from purely prescription-driven CGM toward a hybrid medical, pharmacy and direct-consumer category.

In August 2024, the FDA expanded Insulet SmartAdjust technology to adults aged 18 years and older with type 2 diabetes. This represented the first FDA-cleared automated insulin dosing technology for type 2 diabetes and materially increased the long-term addressable market for AID.

The AID category has also become increasingly competitive following the entry and expansion of systems from Insulet, Tandem, Medtronic and Beta Bionics. Competition is shifting toward simpler meal handling, tighter glucose targets, improved automation, smaller devices and broader CGM compatibility.

During 2025, commercial performance confirmed continued demand for advanced diabetes technology. Dexcom generated approximately USD 4.662 billion in worldwide revenue, with reported U.S. revenue increasing approximately 15%. The company also launched its G7 15 Day system in the United States and received FDA clearance for Smart Basal, a CGM-integrated basal insulin dosing optimizer.

Insulet generated approximately USD 2.7 billion in total 2025 revenue, including approximately USD 1.92 billion in U.S. Omnipod revenue, which grew more than 27% year over year. The company reported more than 600,000 estimated active Omnipod users worldwide at the end of 2025, illustrating rapid adoption of tubeless insulin delivery.

Tandem Diabetes Care exceeded USD 1.0 billion in worldwide sales during 2025, including approximately USD 706.9 million in the United States. It shipped more than 86,000 pumps domestically during the year while expanding CGM integration and its Tandem Mobi platform.

These developments indicate that diabetes-device competition is moving simultaneously in two directions: toward greater automation for insulin-intensive diabetes and toward substantially broader sensing access for people who historically were not candidates for advanced diabetes devices.

 

Conclusion

The U.S. Diabetes Management Devices Market Size & Share is positioned for sustained expansion from approximately USD 21.45 billion in 2025 to USD 59.20 billion by 2035, representing a 10.69% CAGR during 2026–2035.

The long-term opportunity is driven by a combination of high diabetes prevalence, recurring consumable economics, broader CGM reimbursement, automated insulin delivery, rising pump adoption, pharmacy distribution, OTC glucose sensing and increasing integration of devices with smartphones and cloud-based platforms.

Continuous glucose monitoring will remain the largest strategic value pool, but automated insulin delivery is likely to deliver some of the strongest percentage growth. The most consequential commercial development will be expansion into type 2 diabetes. With type 2 accounting for approximately 90%–95% of diagnosed adult diabetes cases, even incremental penetration of CGM and automated insulin delivery can substantially enlarge the addressable device market.

Traditional blood glucose monitoring and injection devices will not disappear. They will remain important for backup testing, cost-sensitive populations, institutional care and patients who prefer injection therapy. Their share of total market value, however, will gradually decline as spending moves toward wearable, connected and recurring sensor-based technologies.

Regionally, the South will remain the largest market, supported by population scale and high diabetes burden. The West is expected to record the fastest growth, reflecting rapid adoption of digital, wearable and consumer-oriented diabetes technologies. The Northeast will remain a premium clinical and innovation market, while the Midwest will provide a stable recurring-demand base supported by established health systems and chronic-disease prevalence.

For manufacturers, investors, distributors and healthcare organizations evaluating this industry, the strategic question is no longer whether diabetes technology adoption will increase. The more important issues are which patient populations will become economically addressable, which reimbursement pathways will dominate, how quickly type 2 diabetes moves into advanced device ecosystems, and which manufacturers can reduce the burden of diabetes management sufficiently to justify premium recurring expenditure.

Companies that combine clinically credible sensing, automated therapeutic decision-making, simple user experience, flexible reimbursement, manufacturing scale, reliable supply, interoperability and demonstrable health-economic value will define the U.S. diabetes management devices market through 2035.

 

TABLE OF CONTENT

1. U.S. Diabetes Management Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing, Analytical Frameworks & Forecasting Models
1.3.6. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Continuous Glucose Monitoring Manufacturers
1.6.2. Blood Glucose Monitoring Device Manufacturers
1.6.3. Insulin Pump and Automated Insulin Delivery Manufacturers
1.6.4. Insulin Injection Device and Smart Pen Manufacturers
1.6.5. Sensor, Semiconductor and Component Suppliers
1.6.6. Endocrinologists, Diabetes Specialty Practices and Health Systems
1.6.7. Pharmacies, DME Suppliers and Specialty Distributors
1.6.8. Commercial Payers, Medicare, Medicaid and PBMs
1.6.9. FDA, CMS and Other Regulatory Stakeholders
1.6.10. Patients, Caregivers and Diabetes Education Providers
What this section provides: This section defines the U.S. diabetes management devices market boundary, study scope, methodology, sizing assumptions and stakeholder ecosystem so clients understand how device revenues, recurring consumables and connected diabetes technologies are measured and validated.

2. U.S. Diabetes Management Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size & Growth Opportunity, 2021–2035
2.8. High-Growth Product and Patient Opportunity Areas
2.9. CGM and Automated Insulin Delivery Adoption Outlook
2.10. Type 2 Diabetes Technology Expansion Opportunity
2.11. Key Strategic Findings for Manufacturers and Investors
What this section provides: This section gives decision-makers a concise view of U.S. market size, historical development, forecast growth, high-value diabetes technology categories, patient adoption trends and the most commercially attractive opportunities through 2035.

3. U.S. Diabetes Management Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Large and Growing U.S. Diabetes Patient Population
3.1.2. Rapid Adoption of Continuous Glucose Monitoring
3.1.3. Expansion of Medicare and Commercial CGM Coverage
3.1.4. Increasing Adoption of Automated Insulin Delivery Systems
3.1.5. Growing Diabetes Technology Penetration in Type 2 Diabetes
3.1.6. Shift Toward Wearable and Tubeless Insulin Delivery
3.1.7. Increasing Pharmacy-Based Diabetes Device Access
3.1.8. Rising Focus on Hypoglycemia Prevention and Time-in-Range Improvement
3.2. Restraints and Their Impact Analysis
3.2.1. High Recurring Cost of Sensors, Pumps and Consumables
3.2.2. Insurance Coverage Gaps and Patient Cost Sharing
3.2.3. Prior Authorization and Benefit Verification Complexity
3.2.4. Technology Access Disparities Across Income and Geography
3.2.5. Device Wearability, Alarm Fatigue and User Adherence Challenges
3.2.6. Product Recall, Cybersecurity and Device Reliability Risks
3.3. Opportunities and Their Impact Analysis
3.3.1. CGM Expansion into Non-Insulin-Treated Type 2 Diabetes
3.3.2. Over-the-Counter Continuous Glucose Monitoring
3.3.3. Automated Insulin Delivery for Type 2 Diabetes
3.3.4. Connected Insulin Pens and Dose-Tracking Technologies
3.3.5. Longer-Wear and Lower-Cost CGM Sensors
3.3.6. Pharmacy-First Device Distribution Models
3.3.7. Remote Diabetes Management and Virtual Endocrinology
3.3.8. Data Analytics and AI-Assisted Diabetes Management
3.4. Challenges and Their Impact Analysis
3.4.1. Patient Onboarding and Training Burden
3.4.2. Endocrinology Workforce Constraints
3.4.3. Interoperability Across CGM, Pump and Software Ecosystems
3.4.4. Reimbursement Complexity Across Payer Types
3.4.5. Manufacturing Scale and Recurring Sensor Supply Requirements
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Diabetes Clinical Workflow Economics Analysis
3.7. Patient Lifetime Value and Recurring Consumables Economics
3.8. Physician Prescribing and Device Selection Behavior
3.9. Payer Coverage and Formulary Influence Analysis
3.10. Patient Switching and Device Ecosystem Lock-In Analysis
What this section provides: This section explains the clinical, reimbursement, behavioral and commercial forces shaping diabetes-device demand and helps clients assess the drivers, barriers, emerging opportunities and execution risks influencing adoption.

4. U.S. Diabetes Management Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Sensor and Wearable Device Manufacturing Economics
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. Continuous Glucose Monitoring Regulatory Pathways
4.7.2. Insulin Pump and Automated Insulin Delivery Regulation
4.7.3. Interoperable CGM and Pump Regulatory Framework
4.7.4. Over-the-Counter Diabetes Device Regulation
4.7.5. Medical Device Software and Cybersecurity Requirements
4.8. CMS Reimbursement and Coverage Landscape
4.8.1. Medicare Continuous Glucose Monitoring Coverage
4.8.2. Medicare Insulin Pump Coverage
4.8.3. Durable Medical Equipment Benefit Dynamics
4.8.4. Pharmacy Benefit Coverage
4.8.5. Medicaid and Commercial Payer Variability
4.9. PBM and Formulary Influence on Device Access
4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Diabetes Prevention and Management Initiatives
4.12. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.13. Data Privacy, Connectivity and Cybersecurity Landscape
4.14. Health Equity and Diabetes Technology Access Analysis
What this section provides: This section gives clients a comprehensive view of regulation, reimbursement, pricing, payer influence, manufacturing, supply-chain conditions, technology access and external forces affecting the U.S. diabetes management devices industry.

5. U.S. Diabetes Management Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
5.2. Continuous Glucose Monitoring Systems
5.2.1. CGM Sensors
5.2.2. Transmitters
5.2.3. Receivers and Readers
5.2.4. Real-Time CGM Systems
5.2.5. Intermittently Scanned CGM Systems
5.2.6. Implantable CGM Systems
5.2.7. Over-the-Counter CGM Systems
5.3. Blood Glucose Monitoring Systems
5.3.1. Blood Glucose Meters
5.3.2. Blood Glucose Test Strips
5.3.3. Lancets and Lancing Devices
5.3.4. Connected Blood Glucose Meters
5.3.5. Hospital and Professional Glucose Monitoring Systems
5.4. Insulin Pumps and Automated Insulin Delivery Systems
5.4.1. Tubed Insulin Pumps
5.4.2. Tubeless/Patch Insulin Pumps
5.4.3. Automated Insulin Delivery Systems
5.4.4. Pump Infusion Sets
5.4.5. Reservoirs, Cartridges and Disposable Pods
5.4.6. Pump Controllers and Accessories
5.5. Insulin Pens, Smart Pens and Injection Devices
5.5.1. Reusable Insulin Pens
5.5.2. Disposable Insulin Pens
5.5.3. Smart and Connected Insulin Pens
5.5.4. Pen Needles
5.5.5. Insulin Syringes
5.5.6. Connected Dose-Tracking Accessories
5.6. Digital, Connected and Other Diabetes Management Devices
5.6.1. Diabetes Device Controllers
5.6.2. Connected Dose Management Devices
5.6.3. Remote Patient Monitoring Hardware
5.6.4. Diabetes Device Data Gateways
5.6.5. Other Emerging Diabetes Management Devices
What this section provides: This section identifies the device categories generating the highest U.S. revenue, recurring consumable opportunity and growth potential, with particular emphasis on CGM, AID systems, pumps and connected insulin administration.

6. U.S. Diabetes Management Devices Market – By Diabetes Type

6.1. Overview
6.1.1. Segment Share Analysis, By Diabetes Type, 2025 & 2035 (%)
6.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
6.2. Type 1 Diabetes
6.2.1. Adult Type 1 Diabetes
6.2.2. Pediatric and Adolescent Type 1 Diabetes
6.2.3. CGM Adoption in Type 1 Diabetes
6.2.4. Insulin Pump Adoption in Type 1 Diabetes
6.2.5. Automated Insulin Delivery Adoption
6.3. Type 2 Diabetes
6.3.1. Insulin-Treated Type 2 Diabetes
6.3.2. Non-Insulin-Treated Type 2 Diabetes
6.3.3. CGM Adoption in Type 2 Diabetes
6.3.4. Insulin Pump and AID Expansion
6.3.5. Connected Injection Device Adoption
6.4. Gestational Diabetes
6.4.1. Glucose Monitoring Requirements
6.4.2. CGM Adoption Opportunity
6.4.3. Insulin Administration Device Demand
6.5. Other Diabetes Types
6.5.1. Monogenic Diabetes
6.5.2. Secondary Diabetes
6.5.3. Other Insulin-Dependent Diabetes Populations
What this section provides: This section analyzes device demand by diabetes population and highlights why type 1 diabetes remains technology-intensive while type 2 diabetes represents the largest incremental expansion opportunity through 2035.

7. U.S. Diabetes Management Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
7.2. Home and Individual Diabetes Management
7.2.1. Adult Home Users
7.2.2. Pediatric and Caregiver-Managed Users
7.2.3. Insulin-Intensive Users
7.2.4. Non-Insulin CGM Users
7.3. Hospitals and Integrated Health Systems
7.3.1. Inpatient Diabetes Management
7.3.2. Outpatient Diabetes Programs
7.3.3. Hospital-Based Endocrinology Programs
7.3.4. Transitional and Post-Discharge Diabetes Management
7.4. Endocrinology and Diabetes Specialty Centers
7.4.1. Independent Endocrinology Practices
7.4.2. Diabetes Specialty Clinics
7.4.3. Academic Diabetes Centers
7.4.4. Diabetes Education and Training Programs
7.5. Home Healthcare, Long-Term Care and Assisted Living
7.5.1. Home Healthcare Agencies
7.5.2. Skilled Nursing Facilities
7.5.3. Assisted Living Facilities
7.5.4. Remote Chronic Care Programs
7.6. Research, Education and Other Clinical Users
7.6.1. Academic Research Institutions
7.6.2. Clinical Trial Centers
7.6.3. Diabetes Education Organizations
7.6.4. Other Healthcare Settings
What this section provides: This section shows where diabetes devices are prescribed, initiated, purchased and used, allowing clients to distinguish the dominant home-use opportunity from strategically important provider and institutional channels.

8. U.S. Diabetes Management Devices Market: Technology, Connectivity & Innovation Ecosystem

8.1. Overview
8.2. Wearable Sensor Technology Evolution
8.2.1. Sensor Accuracy Improvement
8.2.2. Extended Sensor Wear
8.2.3. Reduced Warm-Up Time
8.2.4. Calibration-Free Monitoring
8.2.5. Miniaturization and Wearability
8.3. Automated Insulin Delivery Technology
8.3.1. Hybrid Closed-Loop Systems
8.3.2. Advanced Hybrid Closed-Loop Systems
8.3.3. Algorithm-Based Insulin Adjustment
8.3.4. Automated Correction Bolus Technology
8.3.5. Type 2 Diabetes AID Expansion
8.4. Device Interoperability
8.4.1. Integrated CGM Systems
8.4.2. Alternate Controller Enabled Insulin Pumps
8.4.3. CGM-to-Pump Integration
8.4.4. Multi-Sensor Pump Compatibility
8.4.5. Smartphone and Smartwatch Integration
8.5. Connected Insulin Administration
8.5.1. Smart Insulin Pens
8.5.2. Connected Pen Caps
8.5.3. Dose Capture and Insulin-on-Board Tracking
8.5.4. CGM-Linked Injection Decision Support
8.6. Diabetes Data Platforms and AI
8.6.1. Patient-Facing Applications
8.6.2. Clinician Dashboards
8.6.3. Predictive Glucose Analytics
8.6.4. Alert Prioritization
8.6.5. AI-Assisted Therapy Optimization
8.7. Remote Monitoring and Virtual Diabetes Care
8.8. Cybersecurity and Patient Data Protection
8.9. Emerging Non-Invasive and Minimally Invasive Glucose-Sensing Technologies
8.10. Technology Adoption Curve, 2025–2035
What this section provides: This section evaluates the technology layer reshaping diabetes management without creating an additional formal market segmentation, including sensors, automation, interoperability, connected injections, data platforms and emerging glucose-monitoring technologies.

9. U.S. Diabetes Management Devices Market – By Distribution Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2035 (%)
9.1.2. Segment Market Size and Forecast, 2021–2035 (US$ Billion)
9.2. Retail and Pharmacy Channel
9.2.1. National Retail Pharmacy Chains
9.2.2. Independent Pharmacies
9.2.3. Specialty Pharmacies
9.2.4. Mail-Order Pharmacies
9.2.5. OTC Diabetes Device Retail
9.3. Durable Medical Equipment and Medical Supply Providers
9.3.1. National DME Suppliers
9.3.2. Regional DME Providers
9.3.3. Medicare-Certified Diabetes Supply Providers
9.3.4. Recurring Supply Fulfillment Models
9.4. Direct-to-Consumer and E-commerce
9.4.1. Manufacturer-Direct Channels
9.4.2. Subscription-Based Fulfillment
9.4.3. Online Diabetes Device Retail
9.4.4. OTC CGM Direct-to-Consumer Models
9.5. Hospital and Institutional Procurement
9.5.1. Integrated Health System Contracts
9.5.2. Hospital Procurement
9.5.3. Group Purchasing Organization Contracts
9.5.4. Diabetes Clinic Procurement
9.6. Specialty Distributors and Other Channels
9.6.1. Diabetes Specialty Distributors
9.6.2. Third-Party Supply Fulfillment Providers
9.6.3. Managed-Care and Payer-Directed Networks
What this section provides: This section helps clients understand how diabetes devices reach U.S. patients and how pharmacy benefits, DME coverage, direct-to-consumer models, institutional contracting and specialty distribution influence market access.

10. U.S. Diabetes Management Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Diabetes Prevalence and Diagnosed Population Analysis
10.1.4. Regional CGM and Insulin Pump Adoption Analysis
10.1.5. Medicare, Medicaid and Commercial Coverage Dynamics
10.1.6. Pharmacy and DME Distribution Infrastructure
10.1.7. Endocrinology Access and Rural–Urban Technology Adoption
10.1.8. Regional Competitive and Commercial Opportunity Assessment

10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Diabetes Device Manufacturers and Commercial Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Diabetes Type, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Distribution Channel, 2021–2035 (US$ Billion)
10.2.8. West Region CGM, Pump and AID Adoption Outlook
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035
10.2.9.3. California Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035
10.2.9.5. California Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035
10.2.10.3. Washington Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035
10.2.10.5. Washington Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035
10.2.11.3. Arizona Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035
10.2.11.5. Arizona Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035
10.2.12.3. Colorado Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035
10.2.12.5. Colorado Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035
10.2.13.3. Oregon Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035
10.2.13.5. Oregon Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035
10.2.14.3. Utah Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035
10.2.14.5. Utah Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035
10.2.15.3. Nevada Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035
10.2.15.5. Nevada Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035
10.2.16.3. New Mexico Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035
10.2.16.5. New Mexico Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035
10.2.17.3. Idaho Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035
10.2.17.5. Idaho Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035
10.2.18.3. Montana Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035
10.2.18.5. Montana Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035
10.2.19.3. Wyoming Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035
10.2.19.5. Wyoming Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035
10.2.20.3. Alaska Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035
10.2.20.5. Alaska Market Size and Forecast, By Distribution Channel, 2021–2035
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035
10.2.21.3. Hawaii Market Size and Forecast, By Diabetes Type, 2021–2035
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035
10.2.21.5. Hawaii Market Size and Forecast, By Distribution Channel, 2021–2035

10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Diabetes Device Manufacturers and Commercial Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035
10.3.5. Northeast Region Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035
10.3.7. Northeast Region Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.8. Northeast Region CGM, Pump and AID Adoption Outlook
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035
10.3.9.3. New York Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035
10.3.9.5. New York Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035
10.3.10.3. Massachusetts Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035
10.3.10.5. Massachusetts Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035
10.3.11.3. New Jersey Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035
10.3.11.5. New Jersey Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035
10.3.12.3. Pennsylvania Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035
10.3.12.5. Pennsylvania Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035
10.3.13.3. Connecticut Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035
10.3.13.5. Connecticut Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035
10.3.14.3. Maine Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035
10.3.14.5. Maine Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035
10.3.15.3. Vermont Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035
10.3.15.5. Vermont Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035
10.3.16.3. New Hampshire Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035
10.3.16.5. New Hampshire Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035
10.3.17.3. Rhode Island Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035
10.3.17.5. Rhode Island Market Size and Forecast, By Distribution Channel, 2021–2035
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035
10.3.18.3. Delaware Market Size and Forecast, By Diabetes Type, 2021–2035
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035
10.3.18.5. Delaware Market Size and Forecast, By Distribution Channel, 2021–2035

10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Diabetes Device Manufacturers and Commercial Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035
10.4.5. South Region Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035
10.4.7. South Region Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.8. South Region Diabetes Burden, CGM Access and Rural Adoption Analysis
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035
10.4.9.3. Texas Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035
10.4.9.5. Texas Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035
10.4.10.3. Florida Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035
10.4.10.5. Florida Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035
10.4.11.3. Georgia Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035
10.4.11.5. Georgia Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035
10.4.12.3. North Carolina Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035
10.4.12.5. North Carolina Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035
10.4.13.3. Tennessee Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035
10.4.13.5. Tennessee Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035
10.4.14.3. South Carolina Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035
10.4.14.5. South Carolina Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035
10.4.15.3. Alabama Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035
10.4.15.5. Alabama Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035
10.4.16.3. Mississippi Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035
10.4.16.5. Mississippi Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035
10.4.17.3. Louisiana Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035
10.4.17.5. Louisiana Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035
10.4.18.3. Arkansas Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035
10.4.18.5. Arkansas Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035
10.4.19.3. Kentucky Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035
10.4.19.5. Kentucky Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035
10.4.20.3. Oklahoma Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035
10.4.20.5. Oklahoma Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035
10.4.21.3. Virginia Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035
10.4.21.5. Virginia Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035
10.4.22.3. Maryland Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035
10.4.22.5. Maryland Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035
10.4.23.3. West Virginia Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035
10.4.23.5. West Virginia Market Size and Forecast, By Distribution Channel, 2021–2035
10.4.24. District of Columbia
10.4.24.1. Overview
10.4.24.2. District of Columbia Market Size and Forecast, By Product Type, 2021–2035
10.4.24.3. District of Columbia Market Size and Forecast, By Diabetes Type, 2021–2035
10.4.24.4. District of Columbia Market Size and Forecast, By End User, 2021–2035
10.4.24.5. District of Columbia Market Size and Forecast, By Distribution Channel, 2021–2035

10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Diabetes Device Manufacturers and Commercial Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.8. Midwest Region CGM, Pump and Remote Diabetes Management Outlook
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035
10.5.9.3. Illinois Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035
10.5.9.5. Illinois Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035
10.5.10.3. Ohio Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035
10.5.10.5. Ohio Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035
10.5.11.3. Michigan Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035
10.5.11.5. Michigan Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035
10.5.12.3. Minnesota Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035
10.5.12.5. Minnesota Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035
10.5.13.3. Indiana Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035
10.5.13.5. Indiana Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035
10.5.14.3. Wisconsin Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035
10.5.14.5. Wisconsin Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035
10.5.15.3. Missouri Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035
10.5.15.5. Missouri Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035
10.5.16.3. Iowa Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035
10.5.16.5. Iowa Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035
10.5.17.3. Kansas Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035
10.5.17.5. Kansas Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035
10.5.18.3. Nebraska Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035
10.5.18.5. Nebraska Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035
10.5.19.3. North Dakota Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035
10.5.19.5. North Dakota Market Size and Forecast, By Distribution Channel, 2021–2035
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035
10.5.20.3. South Dakota Market Size and Forecast, By Diabetes Type, 2021–2035
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035
10.5.20.5. South Dakota Market Size and Forecast, By Distribution Channel, 2021–2035
What this section provides: This section delivers detailed four-region and state-level analysis across all 50 states, plus the District of Columbia, allowing clients to identify diabetes-burden hotspots, high-value technology markets, CGM and pump adoption opportunities, reimbursement differences and priority geographies for commercialization.

11. U.S. Diabetes Management Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Overall Diabetes Management Devices Market Share
11.1.2. Continuous Glucose Monitoring Market Share
11.1.3. Insulin Pump and AID Market Share
11.1.4. Blood Glucose Monitoring Market Share
11.1.5. Injection Device Market Share
11.2. Company Positioning Matrix
11.2.1. Market Leaders
11.2.2. Challengers
11.2.3. Technology Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking
11.3.1. Product Portfolio Breadth
11.3.2. U.S. Installed Patient Base
11.3.3. Recurring Consumables Exposure
11.3.4. Reimbursement and Pharmacy Access
11.3.5. Device Interoperability
11.3.6. Clinical Evidence Strength
11.3.7. Manufacturing and Supply-Chain Scale
11.3.8. Digital Ecosystem Strength
11.4. Company Profiles
11.4.1. Abbott Laboratories
11.4.2. DexCom, Inc.
11.4.3. Insulet Corporation
11.4.4. Medtronic plc
11.4.5. Tandem Diabetes Care, Inc.
11.4.6. Beta Bionics, Inc.
11.4.7. Roche Diabetes Care
11.4.8. Ascensia Diabetes Care
11.4.9. LifeScan
11.4.10. Embecta Corp.
11.4.11. Becton, Dickinson and Company
11.4.12. Novo Nordisk
11.4.13. Eli Lilly and Company
11.4.14. Sanofi
11.4.15. Ypsomed Holding AG
11.4.16. Senseonics Holdings, Inc.
11.4.17. AgaMatrix
11.4.18. Trividia Health
11.4.19. Prodigy Diabetes Care
11.4.20. i-SENS, Inc.
11.4.21. Nipro Corporation
11.4.22. Terumo Corporation
11.4.23. Glooko, Inc.
11.4.24. DarioHealth Corp.
11.4.25. Smart Meter LLC
11.5. Company Profile Parameters
11.5.1. Company Overview
11.5.2. Diabetes Management Device Portfolio
11.5.3. U.S. Market Strategy
11.5.4. Financial and Commercial Positioning
11.5.5. Product Pipeline and Innovation Strategy
11.5.6. FDA and Regulatory Updates
11.5.7. Reimbursement and Distribution Strategy
11.5.8. Partnerships and Interoperability Agreements
11.5.9. Recent Developments
11.6. Strategic Partnership and Ecosystem Analysis
11.7. Mergers, Acquisitions and Investment Activity
11.8. New Product Launch and FDA Clearance Benchmarking
What this section provides: This section gives clients competitor benchmarking, market-share visibility, product and ecosystem positioning, innovation intelligence, reimbursement strategy and detailed profiles of 25 companies competing across U.S. diabetes monitoring, insulin delivery and connected-care markets.

12. U.S. Diabetes Management Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Extended-Wear Continuous Glucose Monitoring
12.2.2. Over-the-Counter CGM
12.2.3. Next-Generation Automated Insulin Delivery
12.2.4. Automated Insulin Delivery for Type 2 Diabetes
12.2.5. Smart Insulin Pens and Connected Injection Systems
12.2.6. AI-Assisted Diabetes Management
12.2.7. Remote and Virtual Diabetes Care
12.2.8. Non-Invasive Glucose Monitoring Technologies
12.3. Patient Population Expansion Outlook
12.3.1. Type 1 Diabetes Technology Penetration
12.3.2. Insulin-Treated Type 2 Diabetes
12.3.3. Non-Insulin-Treated Type 2 Diabetes
12.3.4. OTC and Consumer Glucose Monitoring Population
12.4. Emerging Business Trends
12.5. Device-as-a-Platform and Recurring Revenue Models
12.6. Pharmacy Versus DME Channel Evolution
12.7. Business Opportunities for Startups and Existing Players
12.8. Investment Prioritization Matrix
12.9. Technology Adoption Roadmap Through 2035
12.10. Market White-Space Analysis
What this section provides: This section prepares clients for future shifts in diabetes technology, reimbursement, patient eligibility, distribution and business models while identifying disruptive technologies and investment opportunities through 2035.

13. U.S. Diabetes Management Devices Market: Strategic Recommendations

13.1. Recommendations for Diabetes Device Manufacturers
13.2. Recommendations for CGM Manufacturers
13.3. Recommendations for Insulin Pump and AID Manufacturers
13.4. Recommendations for Injection Device Manufacturers
13.5. Recommendations for Hospitals and Endocrinology Providers
13.6. Recommendations for Payers and Population Health Organizations
13.7. Recommendations for Investors and Private Equity Firms
13.8. Recommendations for Pharmacies, DME Providers and Distributors
13.9. Recommendations for New Entrants and Startups
13.10. U.S. Go-to-Market Strategy Considerations
13.11. Payer Access and Reimbursement Strategy
13.12. Patient Acquisition and Retention Strategy
13.13. Product Positioning and Portfolio Expansion Guidance
13.14. State and Regional Market Prioritization
13.15. Partnership, Interoperability and Ecosystem Strategy
What this section provides: This section translates the market intelligence into actionable recommendations for device manufacturers, providers, payers, investors, distributors and new entrants seeking growth, differentiation and stronger U.S. market access.

14. U.S. Diabetes Management Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition and Product Inclusion Limitation
14.3. Data Use Limitation
14.4. Historical Data Limitation
14.5. Forecasting Limitation
14.6. State-Level Market Estimation Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer
14.9. Regulatory and Reimbursement Information Disclaimer
What this section provides: This section clarifies the report’s scope, market-sizing limitations, state-level estimation methodology, legal boundaries, third-party data use and assumptions surrounding regulatory, reimbursement and forecast information.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Diabetes Management Devices Market: Market Definition and Scope
TABLE 3: U.S. Diabetes Management Devices Market: Research Methodology Framework
TABLE 4: U.S. Diabetes Management Devices Market: Key Assumptions
TABLE 5: U.S. Diabetes Management Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Diabetes Management Devices Market: Stakeholder Analysis
TABLE 7: U.S. Diabetes Management Devices Market: Market Sizing and Forecasting Model
TABLE 8: U.S. Diabetes Management Devices Market: Executive Summary Snapshot, 2025
TABLE 9: U.S. Diabetes Management Devices Market: Analyst Viewpoint Summary
TABLE 10: U.S. Diabetes Management Devices Market: Market Attractiveness Index
TABLE 11: U.S. Diabetes Management Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 12: U.S. Diabetes Management Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Diabetes Management Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Diabetes Management Devices Market: High-Growth Opportunity Areas
TABLE 15: U.S. Diabetes Management Devices Market: Drivers; Impact Analysis
TABLE 16: U.S. Diabetes Management Devices Market: Restraints; Impact Analysis
TABLE 17: U.S. Diabetes Management Devices Market: Opportunities; Impact Analysis
TABLE 18: U.S. Diabetes Management Devices Market: Challenges; Impact Analysis
TABLE 19: U.S. Diabetes Management Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 20: U.S. Diabetes Management Devices Market: Diabetes Clinical Workflow Economics Matrix
TABLE 21: U.S. Diabetes Management Devices Market: Patient Lifetime Value and Recurring Consumables Economics
TABLE 22: U.S. Diabetes Management Devices Market: Physician Prescribing and Device Selection Matrix
TABLE 23: U.S. Diabetes Management Devices Market: Payer Coverage and Formulary Influence Matrix
TABLE 24: U.S. Diabetes Management Devices Market: PESTEL Analysis
TABLE 25: U.S. Diabetes Management Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. Diabetes Management Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 27: U.S. Diabetes Management Devices Market: Value Chain Analysis
TABLE 28: U.S. Diabetes Management Devices Market: Supply Chain Analysis
TABLE 29: U.S. Diabetes Management Devices Market: Sensor and Wearable Manufacturing Economics
TABLE 30: U.S. Diabetes Management Devices Market: Application & Innovation Landscape
TABLE 31: U.S. Diabetes Management Devices Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Diabetes Management Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Diabetes Management Devices Market: PBM and Formulary Influence Analysis
TABLE 34: U.S. Diabetes Management Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 35: U.S. Diabetes Management Devices Market: Government Diabetes Initiatives and Public Health Programs
TABLE 36: U.S. Diabetes Management Devices Market: Cybersecurity and Patient Data Protection Landscape
TABLE 37: U.S. Diabetes Management Devices Market: Health Equity and Technology Access Analysis
TABLE 38: U.S. Diabetes Management Devices Market: Product Type Snapshot, 2025
TABLE 39: Segment Dashboard; Definition and Scope, by Product Type
TABLE 40: U.S. Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 41: U.S. Diabetes Management Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 42: U.S. Diabetes Management Devices Market: Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Diabetes Management Devices Market: Blood Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Diabetes Management Devices Market: Insulin Pumps and Automated Insulin Delivery Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Diabetes Management Devices Market: Insulin Pens, Smart Pens and Injection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Diabetes Management Devices Market: Digital, Connected and Other Diabetes Management Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. Diabetes Management Devices Market: Diabetes Type Snapshot, 2025
TABLE 48: Segment Dashboard; Definition and Scope, by Diabetes Type
TABLE 49: U.S. Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 50: U.S. Diabetes Management Devices Market: Segment Share Analysis, by Diabetes Type, 2025 & 2035 (%)
TABLE 51: U.S. Diabetes Management Devices Market: Type 1 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Diabetes Management Devices Market: Type 2 Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Diabetes Management Devices Market: Gestational Diabetes Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Diabetes Management Devices Market: Other Diabetes Types Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Diabetes Management Devices Market: Type 1 Diabetes CGM, Pump and AID Adoption Analysis
TABLE 56: U.S. Diabetes Management Devices Market: Type 2 Diabetes Technology Expansion Analysis
TABLE 57: U.S. Diabetes Management Devices Market: End User Snapshot, 2025
TABLE 58: Segment Dashboard; Definition and Scope, by End User
TABLE 59: U.S. Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 60: U.S. Diabetes Management Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 61: Home and Individual Diabetes Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Endocrinology and Diabetes Specialty Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: Home Healthcare, Long-Term Care and Assisted Living Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: Research, Education and Other Clinical Users Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Diabetes Management Devices Market: Wearable Sensor Technology Landscape
TABLE 67: U.S. Diabetes Management Devices Market: CGM Sensor Wear Duration Benchmarking
TABLE 68: U.S. Diabetes Management Devices Market: Automated Insulin Delivery Technology Matrix
TABLE 69: U.S. Diabetes Management Devices Market: CGM–Insulin Pump Interoperability Matrix
TABLE 70: U.S. Diabetes Management Devices Market: Smartphone and Smartwatch Integration Matrix
TABLE 71: U.S. Diabetes Management Devices Market: Connected Insulin Administration Landscape
TABLE 72: U.S. Diabetes Management Devices Market: Diabetes Data Platform Benchmarking
TABLE 73: U.S. Diabetes Management Devices Market: AI-Assisted Diabetes Management Applications
TABLE 74: U.S. Diabetes Management Devices Market: Remote and Virtual Diabetes Care Landscape
TABLE 75: U.S. Diabetes Management Devices Market: Emerging Non-Invasive Glucose-Sensing Technologies
TABLE 76: U.S. Diabetes Management Devices Market: Technology Adoption Curve, 2025–2035
TABLE 77: U.S. Diabetes Management Devices Market: Distribution Channel Snapshot, 2025
TABLE 78: Segment Dashboard; Definition and Scope, by Distribution Channel
TABLE 79: U.S. Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 80: U.S. Diabetes Management Devices Market: Segment Share Analysis, by Distribution Channel, 2025 & 2035 (%)
TABLE 81: Retail and Pharmacy Channel Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: Durable Medical Equipment and Medical Supply Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: Direct-to-Consumer and E-commerce Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: Hospital and Institutional Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: Specialty Distributors and Other Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 86: U.S. Diabetes Management Devices Market: Pharmacy vs. DME Channel Comparison
TABLE 87: U.S. Diabetes Management Devices Market: Regional Snapshot, 2025
TABLE 88: Segment Dashboard; Definition and Scope, by Geography
TABLE 89: U.S. Diabetes Management Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 90: U.S. Diabetes Management Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 91: U.S. Diabetes Management Devices Market: Regional Diabetes Prevalence and Diagnosed Population Analysis
TABLE 92: U.S. Diabetes Management Devices Market: Regional CGM and Insulin Pump Adoption Analysis
TABLE 93: U.S. Diabetes Management Devices Market: Regional Reimbursement and Distribution Dynamics
TABLE 94: West Region U.S. Diabetes Management Devices Market: Regional Overview and Trends
TABLE 95: West Region U.S. Diabetes Management Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 96: West Region U.S. Diabetes Management Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 97: West Region U.S. Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 98: West Region U.S. Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 99: West Region U.S. Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 100: West Region U.S. Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 101: California Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 102: California Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 103: California Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 104: California Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 105: Washington Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 106: Washington Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 107: Washington Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 108: Washington Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 109: Arizona Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 110: Arizona Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 111: Arizona Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 112: Arizona Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 113: Colorado Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 114: Colorado Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 115: Colorado Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 116: Colorado Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 117: Oregon Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 118: Oregon Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 119: Oregon Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 120: Oregon Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 121: Utah Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 122: Utah Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 123: Utah Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 124: Utah Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 125: Nevada Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 126: Nevada Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 127: Nevada Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 128: Nevada Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 129: New Mexico Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 130: New Mexico Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 131: New Mexico Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 132: New Mexico Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 133: Idaho Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 134: Idaho Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 135: Idaho Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 136: Idaho Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 137: Montana Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 138: Montana Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 139: Montana Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 140: Montana Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 141: Wyoming Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 142: Wyoming Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 143: Wyoming Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 144: Wyoming Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 145: Alaska Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 146: Alaska Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 147: Alaska Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 148: Alaska Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 149: Hawaii Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 150: Hawaii Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 151: Hawaii Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 152: Hawaii Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 153: Northeast Region U.S. Diabetes Management Devices Market: Regional Overview and Trends
TABLE 154: Northeast Region U.S. Diabetes Management Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 155: Northeast Region U.S. Diabetes Management Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 156: Northeast Region U.S. Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 157: Northeast Region U.S. Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 158: Northeast Region U.S. Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 159: Northeast Region U.S. Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 160: New York Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 161: New York Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 162: New York Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 163: New York Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 164: Massachusetts Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 165: Massachusetts Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 166: Massachusetts Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 167: Massachusetts Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 168: New Jersey Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 169: New Jersey Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 170: New Jersey Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 171: New Jersey Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 172: Pennsylvania Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 173: Pennsylvania Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 174: Pennsylvania Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 175: Pennsylvania Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 176: Connecticut Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 177: Connecticut Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 178: Connecticut Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 179: Connecticut Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 180: Maine Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 181: Maine Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 182: Maine Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 183: Maine Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 184: Vermont Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 185: Vermont Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 186: Vermont Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 187: Vermont Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 188: New Hampshire Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 189: New Hampshire Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 190: New Hampshire Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 191: New Hampshire Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 192: Rhode Island Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 193: Rhode Island Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 194: Rhode Island Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 195: Rhode Island Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 196: Delaware Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 197: Delaware Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 198: Delaware Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 199: Delaware Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 200: South Region U.S. Diabetes Management Devices Market: Regional Overview and Trends
TABLE 201: South Region U.S. Diabetes Management Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 202: South Region U.S. Diabetes Management Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 203: South Region U.S. Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 204: South Region U.S. Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 205: South Region U.S. Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 206: South Region U.S. Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 207: Texas Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 208: Texas Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 209: Texas Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 210: Texas Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 211: Florida Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 212: Florida Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 213: Florida Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 214: Florida Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 215: Georgia Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 216: Georgia Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 217: Georgia Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 218: Georgia Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 219: North Carolina Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 220: North Carolina Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 221: North Carolina Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 222: North Carolina Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 223: Tennessee Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 224: Tennessee Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 225: Tennessee Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 226: Tennessee Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 227: South Carolina Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 228: South Carolina Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 229: South Carolina Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 230: South Carolina Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 231: Alabama Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 232: Alabama Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 233: Alabama Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 234: Alabama Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 235: Mississippi Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 236: Mississippi Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 237: Mississippi Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 238: Mississippi Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 239: Louisiana Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 240: Louisiana Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 241: Louisiana Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 242: Louisiana Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 243: Arkansas Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 244: Arkansas Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 245: Arkansas Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 246: Arkansas Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 247: Kentucky Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 248: Kentucky Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 249: Kentucky Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 250: Kentucky Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 251: Oklahoma Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 252: Oklahoma Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 253: Oklahoma Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 254: Oklahoma Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 255: Virginia Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 256: Virginia Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 257: Virginia Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 258: Virginia Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 259: Maryland Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 260: Maryland Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 261: Maryland Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 262: Maryland Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 263: West Virginia Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 264: West Virginia Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 265: West Virginia Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 266: West Virginia Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 267: District of Columbia Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 268: District of Columbia Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 269: District of Columbia Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 270: District of Columbia Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 271: Midwest Region U.S. Diabetes Management Devices Market: Regional Overview and Trends
TABLE 272: Midwest Region U.S. Diabetes Management Devices Market: Key Manufacturers and Commercial Ecosystem
TABLE 273: Midwest Region U.S. Diabetes Management Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 274: Midwest Region U.S. Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 275: Midwest Region U.S. Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 276: Midwest Region U.S. Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 277: Midwest Region U.S. Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 278: Illinois Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 279: Illinois Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 280: Illinois Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 281: Illinois Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 282: Ohio Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 283: Ohio Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 284: Ohio Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 285: Ohio Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 286: Michigan Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 287: Michigan Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 288: Michigan Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 289: Michigan Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 290: Minnesota Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 291: Minnesota Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 292: Minnesota Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 293: Minnesota Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 294: Indiana Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 295: Indiana Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 296: Indiana Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 297: Indiana Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 298: Wisconsin Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 299: Wisconsin Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 300: Wisconsin Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 301: Wisconsin Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 302: Missouri Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 303: Missouri Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 304: Missouri Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 305: Missouri Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 306: Iowa Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 307: Iowa Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 308: Iowa Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 309: Iowa Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 310: Kansas Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 311: Kansas Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 312: Kansas Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 313: Kansas Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 314: Nebraska Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 315: Nebraska Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 316: Nebraska Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 317: Nebraska Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 318: North Dakota Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 319: North Dakota Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 320: North Dakota Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 321: North Dakota Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 322: South Dakota Diabetes Management Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 323: South Dakota Diabetes Management Devices Market, by Diabetes Type, 2021–2035 (US$ Billion)
TABLE 324: South Dakota Diabetes Management Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 325: South Dakota Diabetes Management Devices Market, by Distribution Channel, 2021–2035 (US$ Billion)
TABLE 326: U.S. Diabetes Management Devices Market: Competitive Landscape Snapshot, 2025
TABLE 327: U.S. Diabetes Management Devices Market: Key Company Market Share Analysis, 2025
TABLE 328: U.S. Continuous Glucose Monitoring Market: Key Company Share Analysis, 2025
TABLE 329: U.S. Insulin Pump and Automated Insulin Delivery Market: Key Company Share Analysis, 2025
TABLE 330: U.S. Blood Glucose Monitoring Market: Key Company Share Analysis, 2025
TABLE 331: U.S. Diabetes Management Devices Market: Company Positioning Matrix
TABLE 332: U.S. Diabetes Management Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 333: U.S. Diabetes Management Devices Market: Reimbursement and Distribution Benchmarking
TABLE 334: U.S. Diabetes Management Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 335: Abbott Laboratories: Company Profile
TABLE 336: DexCom, Inc.: Company Profile
TABLE 337: Insulet Corporation: Company Profile
TABLE 338: Medtronic plc: Company Profile
TABLE 339: Tandem Diabetes Care, Inc.: Company Profile
TABLE 340: Beta Bionics, Inc.: Company Profile
TABLE 341: Roche Diabetes Care: Company Profile
TABLE 342: Ascensia Diabetes Care: Company Profile
TABLE 343: LifeScan: Company Profile
TABLE 344: Embecta Corp.: Company Profile
TABLE 345: Becton, Dickinson and Company: Company Profile
TABLE 346: Novo Nordisk: Company Profile
TABLE 347: Eli Lilly and Company: Company Profile
TABLE 348: Sanofi: Company Profile
TABLE 349: Ypsomed Holding AG: Company Profile
TABLE 350: Senseonics Holdings, Inc.: Company Profile
TABLE 351: AgaMatrix: Company Profile
TABLE 352: Trividia Health: Company Profile
TABLE 353: Prodigy Diabetes Care: Company Profile
TABLE 354: i-SENS, Inc.: Company Profile
TABLE 355: Nipro Corporation: Company Profile
TABLE 356: Terumo Corporation: Company Profile
TABLE 357: Glooko, Inc.: Company Profile
TABLE 358: DarioHealth Corp.: Company Profile
TABLE 359: Smart Meter LLC: Company Profile
TABLE 360: U.S. Diabetes Management Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 361: U.S. Diabetes Management Devices Market: Disruptive Technologies Impact Matrix
TABLE 362: U.S. Diabetes Management Devices Market: Extended-Wear CGM Opportunity Assessment
TABLE 363: U.S. Diabetes Management Devices Market: OTC CGM Opportunity Assessment
TABLE 364: U.S. Diabetes Management Devices Market: Next-Generation AID Opportunity Assessment
TABLE 365: U.S. Diabetes Management Devices Market: Type 2 Diabetes AID Expansion Opportunity
TABLE 366: U.S. Diabetes Management Devices Market: Smart Insulin Pen Opportunity Assessment
TABLE 367: U.S. Diabetes Management Devices Market: AI-Assisted Diabetes Management Opportunity
TABLE 368: U.S. Diabetes Management Devices Market: Patient Population Expansion Outlook
TABLE 369: U.S. Diabetes Management Devices Market: Pharmacy vs. DME Channel Evolution
TABLE 370: U.S. Diabetes Management Devices Market: Business Opportunities for Startups and Existing Players
TABLE 371: U.S. Diabetes Management Devices Market: Investment Prioritization Matrix
TABLE 372: U.S. Diabetes Management Devices Market: Technology Adoption Roadmap, 2026–2035
TABLE 373: U.S. Diabetes Management Devices Market: Market White-Space Analysis
TABLE 374: Strategic Recommendations for Diabetes Device Manufacturers
TABLE 375: Strategic Recommendations for CGM Manufacturers
TABLE 376: Strategic Recommendations for Insulin Pump and AID Manufacturers
TABLE 377: Strategic Recommendations for Injection Device Manufacturers
TABLE 378: Strategic Recommendations for Hospitals and Endocrinology Providers
TABLE 379: Strategic Recommendations for Payers and Population Health Organizations
TABLE 380: Strategic Recommendations for Investors and Private Equity Firms
TABLE 381: Strategic Recommendations for Pharmacies, DME Providers and Distributors
TABLE 382: Strategic Recommendations for New Entrants and Startups
TABLE 383: U.S. Diabetes Management Devices Market: Go-to-Market Strategy Considerations
TABLE 384: U.S. Diabetes Management Devices Market: Payer Access and Reimbursement Strategy
TABLE 385: U.S. Diabetes Management Devices Market: Patient Acquisition and Retention Strategy
TABLE 386: U.S. Diabetes Management Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 387: U.S. Diabetes Management Devices Market: Regional and State Market Prioritization
TABLE 388: U.S. Diabetes Management Devices Market: Partnership and Interoperability Strategy
TABLE 389: U.S. Diabetes Management Devices Market: Scope Limitation
TABLE 390: U.S. Diabetes Management Devices Market: Market Definition and Product Inclusion Limitation
TABLE 391: U.S. Diabetes Management Devices Market: Data Use Limitation
TABLE 392: U.S. Diabetes Management Devices Market: Historical Data Limitation
TABLE 393: U.S. Diabetes Management Devices Market: Forecasting Limitation
TABLE 394: U.S. Diabetes Management Devices Market: State-Level Market Estimation Limitation
TABLE 395: U.S. Diabetes Management Devices Market: Legal Disclaimer
TABLE 396: U.S. Diabetes Management Devices Market: Third-Party Data Disclaimer
TABLE 397: U.S. Diabetes Management Devices Market: Regulatory and Reimbursement Information Disclaimer

List of Figures

FIGURE 1: U.S. Diabetes Management Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Diabetes Management Devices Market Ecosystem
FIGURE 4: U.S. Diabetes Management Devices Market Stakeholder Framework
FIGURE 5: Market Sizing and Forecasting Framework
FIGURE 6: U.S. Diabetes Management Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Diabetes Management Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: U.S. Diabetes Management Devices Market Attractiveness Analysis
FIGURE 10: High-Growth Opportunity Areas, 2025–2035
FIGURE 11: U.S. Diabetes Management Devices Market Dynamics
FIGURE 12: Drivers and Restraints Impact Matrix
FIGURE 13: Opportunities and Challenges Impact Matrix
FIGURE 14: Innovation & Patent Landscape, 2021–2025
FIGURE 15: Diabetes Clinical Workflow Economics Framework
FIGURE 16: Patient Lifetime Value and Recurring Consumables Model
FIGURE 17: Physician Prescribing and Device Selection Framework
FIGURE 18: Payer Coverage and Device Access Framework
FIGURE 19: PESTEL Analysis
FIGURE 20: Porter’s Five Forces Analysis
FIGURE 21: Value Chain Analysis
FIGURE 22: Supply Chain Analysis
FIGURE 23: Sensor and Wearable Manufacturing Economics Framework
FIGURE 24: FDA Regulatory and Device Approval Framework
FIGURE 25: CMS Reimbursement and Coverage Framework
FIGURE 26: PBM and Formulary Influence Framework
FIGURE 27: Diabetes Technology Access and Health Equity Framework
FIGURE 28: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 29: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 31: Blood Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Insulin Pumps and Automated Insulin Delivery Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Insulin Pens, Smart Pens and Injection Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Digital, Connected and Other Diabetes Management Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: Product Type Growth Opportunity Matrix, 2025–2035
FIGURE 36: Diabetes Type Segment Market Share Analysis, 2025 & 2035
FIGURE 37: Diabetes Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 38: Type 1 Diabetes Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Type 2 Diabetes Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Type 1 Diabetes CGM, Pump and AID Adoption Analysis
FIGURE 41: Type 2 Diabetes Technology Penetration Opportunity
FIGURE 42: Gestational and Other Diabetes Devices Market Outlook
FIGURE 43: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 44: End User Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 45: Home and Individual Diabetes Management Market Forecast, 2021–2035
FIGURE 46: Hospitals and Integrated Health Systems Market Forecast, 2021–2035
FIGURE 47: Endocrinology and Diabetes Specialty Centers Market Forecast, 2021–2035
FIGURE 48: Home Healthcare and Long-Term Care Diabetes Device Opportunity
FIGURE 49: End User Adoption and Purchasing Influence Matrix
FIGURE 50: CGM Technology Evolution Roadmap
FIGURE 51: CGM Sensor Wear Duration Innovation Roadmap
FIGURE 52: Automated Insulin Delivery Technology Framework
FIGURE 53: Hybrid Closed-Loop and Advanced Hybrid Closed-Loop Evolution
FIGURE 54: CGM–Insulin Pump Interoperability Ecosystem
FIGURE 55: Smartphone and Smartwatch Integration Ecosystem
FIGURE 56: Connected Insulin Administration Ecosystem
FIGURE 57: Diabetes Data Platform and Clinician Workflow Framework
FIGURE 58: AI-Assisted Diabetes Management Opportunity Map
FIGURE 59: Remote and Virtual Diabetes Care Model
FIGURE 60: Emerging Glucose-Sensing Technology Roadmap
FIGURE 61: Distribution Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 62: Distribution Channel Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 63: Retail and Pharmacy Channel Market Forecast, 2021–2035
FIGURE 64: DME and Medical Supply Provider Market Forecast, 2021–2035
FIGURE 65: Direct-to-Consumer and E-commerce Market Forecast, 2021–2035
FIGURE 66: Hospital and Institutional Procurement Market Forecast, 2021–2035
FIGURE 67: Pharmacy vs. DME Diabetes Device Access Model
FIGURE 68: U.S. Diabetes Device Distribution Ecosystem
FIGURE 69: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 70: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Regional Diabetes Prevalence and Device Adoption Opportunity Map
FIGURE 72: West Region U.S. Diabetes Management Devices Market Share and Leading Players, 2025
FIGURE 73: West Region Market Share Analysis by State, 2025
FIGURE 74: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: California Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Washington Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Arizona Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Colorado Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Oregon Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Utah Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Nevada Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: New Mexico Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Idaho Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Montana Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Wyoming Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Alaska Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Hawaii Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Northeast Region U.S. Diabetes Management Devices Market Share and Leading Players, 2025
FIGURE 89: Northeast Region Market Share Analysis by State, 2025
FIGURE 90: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: New York Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Massachusetts Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: New Jersey Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Pennsylvania Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Connecticut Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Maine Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Vermont Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: New Hampshire Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Rhode Island Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Delaware Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: South Region U.S. Diabetes Management Devices Market Share and Leading Players, 2025
FIGURE 102: South Region Market Share Analysis by State, 2025
FIGURE 103: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Texas Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Florida Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Georgia Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: North Carolina Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Tennessee Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: South Carolina Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Alabama Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Mississippi Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Louisiana Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Arkansas Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Kentucky Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Oklahoma Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Virginia Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Maryland Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: West Virginia Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: District of Columbia Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Midwest Region U.S. Diabetes Management Devices Market Share and Leading Players, 2025
FIGURE 121: Midwest Region Market Share Analysis by State, 2025
FIGURE 122: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: Illinois Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: Ohio Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 125: Michigan Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 126: Minnesota Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 127: Indiana Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 128: Wisconsin Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 129: Missouri Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 130: Iowa Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 131: Kansas Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 132: Nebraska Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 133: North Dakota Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 134: South Dakota Diabetes Management Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 135: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 136: U.S. Continuous Glucose Monitoring Market Share Analysis, 2025
FIGURE 137: U.S. Insulin Pump and Automated Insulin Delivery Market Share Analysis, 2025
FIGURE 138: Company Positioning Matrix
FIGURE 139: Key Player Product Portfolio Benchmarking
FIGURE 140: Reimbursement and Distribution Benchmarking of Key Players
FIGURE 141: Strategic Partnerships, M&A, FDA Clearances and Product Launches
FIGURE 142: U.S. Diabetes Management Device Competitive Innovation Roadmap
FIGURE 143: Future Market Scenario Analysis, 2026–2035
FIGURE 144: Disruptive Technologies Impact Matrix
FIGURE 145: Extended-Wear CGM Growth Roadmap
FIGURE 146: OTC Continuous Glucose Monitoring Growth Roadmap
FIGURE 147: Automated Insulin Delivery Adoption Roadmap
FIGURE 148: Type 2 Diabetes Technology Expansion Opportunity
FIGURE 149: Smart Insulin Pen Opportunity Map
FIGURE 150: AI-Assisted Diabetes Management Growth Roadmap
FIGURE 151: Patient Population Expansion Opportunity, 2026–2035
FIGURE 152: Pharmacy vs. DME Channel Evolution, 2026–2035
FIGURE 153: Diabetes Technology Adoption Roadmap, 2026–2035
FIGURE 154: Investment Prioritization Matrix
FIGURE 155: Market White-Space Opportunity Map
FIGURE 156: Strategic Growth Roadmap for U.S. Diabetes Device Companies
FIGURE 157: U.S. Diabetes Management Devices Go-to-Market Strategy Framework
FIGURE 158: Payer Access and Reimbursement Strategy Framework
FIGURE 159: Patient Acquisition and Retention Framework
FIGURE 160: Regional and State Market Prioritization Matrix
FIGURE 161: Product Positioning and Portfolio Expansion Framework
FIGURE 162: Partnership and Interoperability Strategy Framework
FIGURE 163: Report Scope and Market Boundary Framework
FIGURE 164: Data and Forecasting Limitation Framework
FIGURE 165: State-Level Estimation Limitation Framework
FIGURE 166: Regulatory, Reimbursement and Legal Disclaimer Framework